Novartis, the Swiss pharmaceutical company, has revised its full-year earnings forecast for 2023 upwards for the third time. This adjustment is attributed to expense reductions and stronger than anticipated pricing
Explore the fiscal landscape of Novartis for the year ending December 2023 with our insightful analysis